BTIG Research Forecasts Strong Price Appreciation for Guardant Health (NASDAQ:GH) Stock

Guardant Health (NASDAQ:GH) had its target price increased by BTIG Research from $140.00 to $145.00 in a report issued on Friday, Marketbeat reports. The firm currently has a “buy” rating on the stock. BTIG Research’s price objective suggests a potential upside of 36.30% from the company’s current price.

A number of other brokerages have also recently weighed in on GH. Guggenheim lifted their price target on shares of Guardant Health from $115.00 to $135.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Mizuho set a $135.00 target price on Guardant Health in a report on Friday, January 9th. Robert W. Baird initiated coverage on Guardant Health in a research note on Tuesday. They issued an “outperform” rating and a $120.00 target price for the company. Morgan Stanley lifted their price objective on Guardant Health from $105.00 to $130.00 and gave the company an “overweight” rating in a report on Monday, December 1st. Finally, Stifel Nicolaus boosted their price objective on Guardant Health from $100.00 to $120.00 and gave the company a “buy” rating in a research report on Friday, January 9th. Twenty-two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Guardant Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $108.59.

Guardant Health Price Performance

Shares of GH stock opened at $106.38 on Friday. The stock has a market cap of $13.41 billion, a PE ratio of -33.14 and a beta of 1.63. The stock has a 50-day moving average of $106.67 and a 200-day moving average of $85.53. Guardant Health has a one year low of $34.88 and a one year high of $120.74.

Guardant Health (NASDAQ:GH) last released its quarterly earnings data on Thursday, February 19th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The company had revenue of $281.27 million for the quarter, compared to analyst estimates of $269.74 million. Guardant Health’s revenue was up 39.4% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.62) earnings per share. As a group, research analysts anticipate that Guardant Health will post -2.9 earnings per share for the current year.

Insider Activity at Guardant Health

In other Guardant Health news, insider Chris Freeman sold 31,452 shares of the company’s stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $103.07, for a total transaction of $3,241,757.64. Following the completion of the transaction, the insider owned 25,987 shares of the company’s stock, valued at $2,678,480.09. This represents a 54.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Helmy Eltoukhy sold 90,565 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $103.82, for a total transaction of $9,402,458.30. Following the transaction, the chief executive officer directly owned 2,047,143 shares of the company’s stock, valued at $212,534,386.26. This represents a 4.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 434,511 shares of company stock valued at $45,580,887 over the last ninety days. Company insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. V Square Quantitative Management LLC acquired a new stake in shares of Guardant Health in the 4th quarter valued at approximately $27,000. Chesapeake Asset Management LLC bought a new stake in Guardant Health during the fourth quarter worth $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Guardant Health in the fourth quarter valued at $31,000. Elyxium Wealth LLC bought a new position in shares of Guardant Health in the 4th quarter valued at about $35,000. Finally, Parallel Advisors LLC increased its stake in shares of Guardant Health by 164.7% during the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after purchasing an additional 219 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Key Guardant Health News

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Q4 revenue beat and strong top-line growth — Guardant reported revenue of $281.3M (+39% YoY), driven by oncology test volumes, which suggests healthy demand and execution on growth levers. Business Wire Q4 results
• Positive Sentiment: FY-2026 revenue guidance raised to about $1.3B, above the ~$1.2B consensus, giving visible top‑line momentum for next year (EPS guidance was not meaningfully updated in the releases). Guidance press release
• Neutral Sentiment: Robert W. Baird initiated research coverage on Guardant, which can increase analyst attention and liquidity; the initiation may influence sentiment depending on the published rating and price target. American Banking News
• Neutral Sentiment: Full Q4 earnings call transcript is available for management commentary on growth drivers, margin trajectory, and product cadence — useful for parsing the outlook and execution details behind the guidance. Earnings call transcript
• Neutral Sentiment: Analyst/metrics coverage pieces (Zacks) provide deeper look at which line items out- or underperformed versus Street estimates. Zacks metrics analysis
• Negative Sentiment: EPS missed expectations: GAAP loss of $0.50/sh vs. consensus -$0.43, continuing the company’s negative earnings trend and keeping profitability concerns front-and-center for investors. Zacks Q4 loss report

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.